PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
07-Jan-2026 eGenesis to Present at 44th Annual J.P. Morgan Healthcare Conference Businesswire
07-Jan-2026 NeuraLight Reaches Key Milestone with Completion of International Multicenter Parkinson’s Clinical Trial Businesswire
07-Jan-2026 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
07-Jan-2026 Evaluate Releases Look into Pharma Market in 2026 Evaluate
07-Jan-2026 Vygon appoints new general manager to lead UK subsidiary Vygon
07-Jan-2026 Nuevocor Appoints Al Gianchetti as Chief Executive Officer Businesswire
07-Jan-2026 Stylus Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference Businesswire
07-Jan-2026 Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones Businesswire
07-Jan-2026 Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy Businesswire
07-Jan-2026 SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026 Businesswire
07-Jan-2026 EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan Businesswire
07-Jan-2026 Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC Businesswire
07-Jan-2026 Breast cancer tops list of most-studied diseases for fifth consecutive year, Phesi annual analysis finds Phesi
07-Jan-2026 Merck to Complete Acquisition of Cidara Therapeutics Businesswire
07-Jan-2026 Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD Businesswire
07-Jan-2026 Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3 Businesswire
07-Jan-2026 Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform Businesswire
07-Jan-2026 TrialAssure Establishes Physical Presence in The Netherlands to Advance Clinical Trial Transparency and Data Sharing Across Europe TrialAssure
07-Jan-2026 Bial launches KYNMOBI® (apomorphine hydrochloride) in the United Kingdom Bial
07-Jan-2026 Bial launches KYNMOBI® (apomorphine hydrochloride) in the United Kingdom Bial